Encyclopedia of Molecular Pharmacology

Living Edition
| Editors: Stefan Offermanns, Walter Rosenthal

Monoamine Oxidases and Their Inhibitors

  • Moussa B. H. YoudimEmail author
  • Keith F. Tipton
Living reference work entry
DOI: https://doi.org/10.1007/978-3-030-21573-6_191-1



Monoamine oxidase (amine:oxygen oxidoreductase (deaminating); EC; MAO) exists in two forms, named type A and type B. They are responsible for oxidative deamination of primary, secondary, and some tertiary amines, including the neurotransmitters, noradrenaline, dopamine, and serotonin (5-hydroxytryotamine; 5-HT), the hormone adrenaline, and trace amines, such as tyramine, tryptamine, and 2-phenylethylamine. Their nonselective and selective inhibitors are employed for the treatment of depressive illness and Parkinson’s disease.

Reaction Mechanism of Monoamine Oxidase

The role of monoamine oxidase in terminating the action of the aminergic neurotransmitters and dietary amines has been extensively studied; less attention has been paid to the functions of the products formed in the MAO reactions that include aldehyde and acidic metabolites.
This is a preview of subscription content, log in to check access.

Reading List

  1. Gillman PK (2018) A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths. J Neural Transm (Vienna) 125(11):1707–1717CrossRefGoogle Scholar
  2. Iacovino LG, Magnani F, Binda C (2018) The structure of monoamine oxidases: past, present, and future. J Neural Transm 125:1567–1579CrossRefGoogle Scholar
  3. Shih JC (2018) Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy. J Neural Transm (Vienna) 125(11):1553–1566CrossRefGoogle Scholar
  4. Shih JC, Chen K (2004) Regulation of MAO-A and MAO-B gene expression. Curr Med Chem 11:1995–2005CrossRefGoogle Scholar
  5. Tábi T, Vécsei L, Youdim MB, Riederer P, Szökő É (2019) Selegiline: a molecule with innovative potential. J Neural Transm (Vienna).  https://doi.org/10.1007/s00702-019-02082-0. [Epub ahead of print]
  6. Tipton KF (2018) 90 years of monoamine oxidase: some progress and some confusion. J Neural Transm 125:1519–1551CrossRefGoogle Scholar
  7. Tripathi RKP, Ayyannan SR (2019) Monoamine oxidase-B inhibitors as potential neurotherapeutic agents: an overview and update. Med Res Rev 39(5):1603–1706CrossRefGoogle Scholar
  8. Yeung AWK, Georgieva MG, Atanasov AG, Tzvetkov NT (2019) Monoamine oxidases (MAOs) as privileged molecular targets in neuroscience: research literature analysis. Front Mol Neurosci 12:143CrossRefGoogle Scholar
  9. Youdim MBH (2018) Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases. J Neural Transm (Vienna) 125(11):1719–1733CrossRefGoogle Scholar
  10. Youdim MB, Riederer PF (2007) Monoamine oxidase A and B inhibitors in Parkinson’s disease. Handbook Clin Neurol 84:93–120CrossRefGoogle Scholar
  11. Youdim MB, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7(4):295–309CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg New York 2020

Authors and Affiliations

  1. 1.Eve Topf and NPF Centers of Excellence for Neurodegenerative Diseases Research, Department of Pharmacology, Faculty of MedicineTechnion-Rappaport FamilyHaifaIsrael
  2. 2.School of Biochemistry and ImmunologyTrinity College, University of DublinDublin 2Ireland